Publicaciones en las que colabora con LUIS HERMENEGILDO MARTIN ARIAS (15)

2023

  1. Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions

    Expert Opinion on Drug Safety, Vol. 22, Núm. 1, pp. 71-79

2022

  1. Haplotypes in the GC, CYP2R1 and CYP24A1 Genes and Biomarkers of Bone Mineral Metabolism in Older Adults

    Nutrients, Vol. 14, Núm. 2

  2. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study

    Annals of medicine, Vol. 54, Núm. 1, pp. 379-392

2021

  1. A multicenter case–control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Corrigendum: Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study (Frontiers in Pharmacology, (2020), 11, 10.3389/fphar.2020.00860)

    Frontiers in Pharmacology

  2. Hydroxychloroquine and Potential Drug Interactions in Older Adults

    Archivos de Bronconeumologia, Vol. 56, Núm. 10, pp. 679-681

  3. Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study

    Frontiers in Pharmacology, Vol. 11

2015

  1. Emergency contraceptive pill safety profile. Comparison of the results of a follow-up study to those coming from spontaneous reporting

    Pharmacoepidemiology and Drug Safety, Vol. 24, Núm. 1, pp. 93-97

2013

  1. Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study

    European Journal of Clinical Pharmacology, Vol. 69, Núm. 3, pp. 559-564

2012

  1. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): Changes in the consumption pattern following the introduction of extended release methylphenidate

    Pharmacoepidemiology and Drug Safety, Vol. 21, Núm. 4, pp. 435-441

2011

  1. Adverse events associated with pandemic influenza vaccines: Comparison of the results of a follow-up study with those coming from spontaneous reporting

    Vaccine, Vol. 29, Núm. 3, pp. 519-522

2010

  1. Response to rupatadine and heart rhythm disturbances

    Clinical Pharmacology and Therapeutics

2009

  1. Heart rhythm disturbances associated with rupatadine: A case series from the Spanish and Portuguese pharmacovigilance systems

    Clinical Pharmacology and Therapeutics, Vol. 85, Núm. 5, pp. 481-484

2007

  1. Gynaecomastia associated with proton pump inhibitors: A case series from the Spanish pharmacovigilance system

    Drug Safety, Vol. 30, Núm. 6, pp. 527-531

2006

  1. HMG CoA reductase inhibitors and impotence: Two case series from the Spanish and French drug monitoring systems

    Drug Safety, Vol. 29, Núm. 2, pp. 143-149